Thus, gemcitabine-mediated ROS can be inferred to further induce ferroptosis in cancer cells, implying that we can enhance the efficacy of gemcitabine or reverse gemcitabine resistance by inducing ferroptosis through targeting Nrf2, SLC3A2, SLC7A11, and GPX4 (Figure 4). This evidence concerns the gene NFE2L2 and cancer.